Login to Your Account

AbbVie, InterMune Sue EMA on Data Confidentiality

Wednesday, March 13, 2013
AbbVie Inc. and InterMune Inc. could derail the European Medicines Agency's (EMA) carefully timetabled introduction of a new data transparency regime on Jan. 1, 2014, by seeking court injunctions preventing the disclosure of clinical trial data for their respective principal products, Humira (adalimumab) and Esbriet (perfidenone).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription